Article Per Year (5 Year)
p-Index From 2021 - 2026
0.659
P-Index
This Author published in this journals
All Journal Jurnal Ilmu Farmasi dan Farmasi Klinik (Journal of Pharmaceutical Science and Clinical Pharmacy)
Sri Susilowati
Departement Farmakologi dan Farmasi Klinik Fakultas Farmasi, Universitas Wahid Hasyim
Medicine & Pharmacology

Published : 3 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 3 Documents
Search

 1 
Evaluasi Penggunaan Kemoterapi pada Pasien Kanker Payudara di Rumah Sakit Islam Sultan Agung Semarang Tahun 2022 Nadia Zulfana Firdaus; Sri Susilowati
Jurnal Ilmu Farmasi dan Farmasi Klinik Vol 20, No 2 (2023)
Publisher : Universitas Wahid Hasyim Semarang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31942/jiffk.v20i2.9902

Abstract

Kemoterapi adalah salah satu pengobatan kanker payudara. Pengobatan kemoterapi perlu dilakukan dengan tepat untuk menghindari terjadinya pemborosan, meningkatnya efek samping obat, dan kegagalan terapi. Tujuan penelitian ini untuk mengetahui pola penggunaan kemoterapi dan mengevaluasi ketepatannya yang meliputi tepat indikasi, tepat pasien, tepat regimen obat, tepat dosis, dan tepat cara pemberian pada pasien kanker payudara di Rumah Sakit Islam Sultan Agung Semarang tahun 2022. Penelitian dilakukan secara observasional dengan desain cross-sectional. Data diperoleh secara retrospektif dari rekam medis pasien. Pengambilan sampel menggunakan metode purposive sampling sehingga didapatkan 56 sampel yang memenuhi kriteria inklusi dan eksklusi. Evaluasi dilakukan menggunakan standar Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara Kementerian Kesehatan Republik Indonesia tahun 2018 dan British Columbia Cancer Agency Clinical Pharmacy Guide kemudian data dianalisa secara deskriptif. Hasil penelitian menunjukkan bahwa regimen obat kemoterapi yang paling banyak digunakan adalah doksetaksel dan doksorubisin (64,3%), obat penunjang yang diberikan seluruhnya adalah kombinasi difenhidramin, ranitidin, ondansetron, dan deksametason (100%). Evaluasi ketepatan penggunaan obat menunjukkan tepat indikasi (100%), tepat pasien (100%), tepat regimen obat (82,2%), tepat dosis (8,8%), dan tepat rute pemberian obat (100%). Kesimpulannya bahwa penggunaan kemoterapi pada pasien kanker payudara di Rumah Sakit Islam Sultan Agung masih terdapat ketidaktepatan terkait regimen dan dosis.
Analisis Drugs Related Problems pada Pasien Kanker Payudara di Rumah Sakit Umum Daerah KRMT Wongsonegoro Semarang Tahun 2022 Sri Susilowati; Firda Shely Septasari
Jurnal Ilmu Farmasi dan Farmasi Klinik No 1 (2024): JIFFK Special Edition Suppl. 2
Publisher : Universitas Wahid Hasyim Semarang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31942/jiffk.v2i1.11712

Abstract

Drugs Related Problems (DRPs) are problems related to patient treatment that can affect the effectiveness and safety of therapy. Breast cancer patients who receive chemotherapy usually consists of a combination of several drugs. Administration of a combination of chemotherapy drugs can cause DRPs. This study aims to determine the actual and potential incidence of DRPs and their causes in breast cancer patients at the KRMT Wongsonegoro Regional General Hospital, Semarang in 2022. This research was conducted observationally with a cross-sectional research design and retrospective data collection by observing medical record data of breast cancer patients. There were 30 samples that met the inclusion and exclusion criteria. The classification of DRPs refers to the Regulation of the Minister of Health of the Republic of Indonesia Number 34 of 2021 concerning Standards of Pharmaceutical Services in Clinics. DRPs were analyzed using the National Guidelines for Medical Services for Breast Cancer Management in 2018. Analysis of potential drug interactions used medscape.com. Data analysis was carried out descriptively. The results showed that the most frequently used chemotherapy regimen was cyclophosphamide + doxorubicin + fluorouracil (76.67%). All patient samples experienced actual and potential DRPs with the cause being indication without medication (46.67%), medication without indication (0%), too high a dose (90%), too low a dose (100%), side effects undesired (100%), potential drug interactions (100%) and duration of treatment (53.2%). The prevalence of DRPs in our setting was high so that it could affect therapy outcomes of patient. Therefore, it is hoped that there will be an evaluation to reduce the prevalence of DRPs, by optimizing clinical pharmacy service practices such as reviewing prescriptions, monitoring effectiveness therapy and adverse drug reaction also conducting interprofessional collaboration.
Pattern and Appropriateness of Antiemetic Drug Utilization in Breast Cancer Patients at Sultan Agung Islamic Hospital, Semarang, Indonesia Sri Susilowati; Amelia Tivani Sari
Jurnal Ilmu Farmasi dan Farmasi Klinik Vol. 23 No. 1 (2026): Jurnal Ilmu Farmasi dan Farmasi Klinis (JIFFK)
Publisher : Universitas Wahid Hasyim Semarang

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.31942/jiffk.v23i1.15207

Abstract

Chemotherapy-induced nausea and vomiting (CINV) are common adverse effects experienced by patients undergoing chemotherapy. Antiemetic therapy is a key strategy for the prevention and management of CINV; therefore, appropriate antiemetic use is essential. This study aimed to determine the patterns of chemotherapy and antiemetic utilization and to evaluate the appropriateness of antiemetic therapy based on the emetogenic risk of chemotherapy agents and antiemetic dosing standards in breast cancer patients at Sultan Agung Islamic Hospital, Semarang, Indonesia, in accordance with the National Comprehensive Cancer Network (NCCN) Guidelines 2024. The study was conducted observationally using a cross-sectional design with retrospective data collection from patients’ medical records. A total of 84 breast cancer patients were included through purposive sampling, according to predefined inclusion and exclusion criteria. The most frequently used chemotherapy regimen was paclitaxel–cisplatin (26%). Antiemetics were administered both prophylactically and post-chemotherapy, with ondansetron combined with dexamethasone as the most commonly used regimen (99.4%), along with ranitidine and diphenhydramine as adjunctive therapy. Evaluation of antiemetic appropriateness showed that 98.8% of patients did not receive antiemetic therapy consistent with the emetogenic risk of the chemotherapy agents, particularly among those receiving high-emetogenic-risk regimens. In addition, dose evaluation revealed inappropriate dexamethasone dosing, primarily due to underdosing and non-standard dosing frequency compared with the NCCN Guidelines 2024. Overall, antiemetic use was largely inconsistent with NCCN Guidelines 2024 recommendations, potentially compromising optimal CINV prevention in highly emetogenic chemotherapy.
Co-Authors Amelia Tivani Sari Firda Shely Septasari Nadia Zulfana Firdaus